

CURRICULUM VITAE

Name Karl D. Kieburtz

Date and Place of Birth _____

Social Security : _____

Education 1980 - B.A., Magna Cum Laude, Neuroscience and Religion, Amherst College, Amherst MA.

1985 - M.P.H., University of Rochester, Rochester, NY. Thesis: Physician prescribing in HMOs

1985 - M.D., University of Rochester, Rochester, NY.

Professional History

1985-86 Intern, Family Medicine, Highland Hospital, Rochester, New York

1986-88 Resident, Neurology, Strong Memorial Hospital, Rochester, New York

1988-89 Chief Resident, Neurology, Strong Memorial Hospital, Rochester, New York

1989-91 Fellow in Experimental Therapeutics (NIH funded training grant NS07338), Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York

1991-92 Senior Instructor and Fellow, Department of Neurology. Senior Instructor, Department of Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York

1992-95 Assistant Professor, Departments of Neurology and Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York

1993- Director, Clinical Trials Coordination Center, Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York

1995-00 Associate Professor, Departments of Neurology and Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York

1999- Chief, Movement and Inherited Neurological Disorders Unit, Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York

2000- Professor, Departments of Neurology and Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York

Honors

Frank Dow Award in Chemistry, Amherst College, 1980
Logan Clendenning Fellowship in the History of Medicine, 1982
Medical Student Research Fellow, University of Rochester, 1985
George W. Merck Dean's Teaching Scholar, University of Rochester School of Medicine 1994-1997
The Best Doctors in America, Woodward/White, Inc., 2nd edition, 1994

Medical Licenses and Certifications

State of New York, Board of Medical Examiners, 1985
Diplomate, American Board of Psychiatry and Neurology (Neurology), 1990

Research Support

Medical Director and Steering Committee member, Deprenyl and Tocopherol Antioxidant Therapy of Parkinsonism (DATATOP), NS24778, NINDS, NIH. 11/89-4/94.

Principal Investigator, Dideoxyinosine treatment of AIDS Dementia, industry sponsored clinical trial, 10/90-11/91, total costs _____

Medical Director and Steering Committee member, Parkinson Study Group START clinical trials, industry sponsored, 11/1/90-4/30/92, total costs \$ _____

Member, Neurology Core Committee, AIDS Clinical Trial Group, National Institute of Allergy and Infectious Disease, NIH, 7/90-7/94, 2U01AI27658.

Medical Director and Steering Committee member, Parkinson Study Group ROADS clinical trial, 4/92-4/94, industry sponsored, total costs _____

Medical Director, Parkinson Study Group, BLIND-DATE clinical trial, 3/93-1/95, industry sponsored, total costs _____

Principal Investigator, Glutamate Antagonist Tolerability in Huntington's Disease, industry sponsored clinical trial, 7/1/93-6/30/94, total costs _____

Medical Director, Parkinson Study Group, STEP-UP clinical trial, 10/93-6/95, industry sponsored, total costs _____

Sub-proposer and Consultant, European Network for Striatal Transplantation in Huntington's Disease (NEST-HD): preclinical development and clinical trial methodology, sponsored by the European Economic Community, total costs _____

Site Principal Investigator, Experimental Therapeutics of HIV Neurology (part of Neurologic AIDS Research Consortium Program Project, _____), NINDS, NIH _____ 12/1/93-11/30/95.

Research Support (continued)

Medical Director, Parkinson Study Group. SEESAW clinical trial, 11/93-12/95, industry sponsored, total costs _____

Co-Principal Investigator _____ Dana Foundation Consortium For The Treatment of HIV Dementia And Related Disorders, 1/94-12/96, total costs _____

Study Chair, A Double Blind Study of Amitriptyline and Mexilitine for Painful HIV Neuropathy. AIDS Clinical Trials Group, Protocol 242, 2/94-2/96.

Medical Director (_____), Clozapine for Psychosis in PD. FDA, Orphan Drug Div. 7/94-6/97, _____

Medical Director (I Shoulson PI) Investigation of Tolerability of OPC-14117 in Huntington's disease. 9/94-9/95, total costs _____

Principal Investigator, Trial of a Glutamate Antagonist in PD and MSA, 9/95-9/96, industry sponsored, total cost _____

Director of Coordination Center _____ , Evaluation of SPECT Imaging in The Diagnosis of PD, 9/95-9/96, industry sponsored, total cost _____

Director of Coordination Center (_____), Comparison of Levodopa and a Dopamine Agonist in PD, 10/95-10/02, industry sponsored, total cost _____

Director of Coordination Center (_____), Study of a Dopamine Agonist in Minority Persons, 10/95-3/97, total costs _____

Director of Coordination Center _____ Treatment of ADHD in Children with Tourette's, 7/96-7/99, NIH NINDS, RO1 NS33654.

Principal Investigator. Interaction Study of Remacemide and Levodopa in Parkinson's Disease, 10/96-11/97, industry sponsored, total costs _____

Project Principal Investigator _____ Washington University, PPG PI), NIH, P01 NS32228. Clinical Trials Unit in HIV Dementia, NINDS, 12/93-4/02. _____

Principal Investigator. Co-Enzyme Q10 and Remacemide Evaluation in Huntington's Disease. NIH, RO1 NS35284. 5/97-5/01. _____

Data Management Core Director _____ Neurocognitive Function, HIV Load and Surrogate Markers (NEAD). NIH, P01 NS36519-01A1. 2/98-1/03, _____

Coordination Center Director (_____ NIH, RO1 NS34796-01A1. Earlier vs. Later L-dopa in Parkinson's Disease. 6/98-6/01. _____

Co-Principal Investigator (_____ NIH RO1 NS36714. Effects of Coenzyme Q10 in Patients With Early, Untreated Parkinson's Disease. 6/98-6/01. _____

Research Support (continued)

Principal Investigator, NINDS, NS02122, Midcareer Investigator Award in Patient-Oriented Research, 1/99-12/04, _____

Coordination Center Director _____ NIH R21 NS37897, A Multi-center Randomized Clinical Trial for Early Treatment of Epilepsy, 7/99-6/00, _____

Chair, Safety Monitoring Committee (_____ 5U01-AG010483 Alzheimer's Disease Cooperative Study, 9/98-6/06, total Costs _____

Coordination Center Director, Topical Dopamine Agonist in PD, industry sponsored, 6/99-12/00, total costs \$ _____

Coordination Center Director, Monoamine Oxidase Inhibitor in PD, industry sponsored, 10/97-10/00 _____

Coordination Center Director, Ethylester of Levodopa in PD, industry sponsored, 6/99-6/02, _____

Project Co-PI _____, Targeted Neuroprotection for HIV-1 Associated Neurologic Disease, NIH PO1 MH64570, 7/01-6/05, _____

Coordination Center Director _____, PANDAS and Strep Infection: Are they linked? NIH NS42240 7/01-6/05, _____

Principal Investigator, Neuroprotection Studies in PD: A Coordinating Center, NIH, NINDS NS43128, 9/01-7/06.

Coordination Center Director _____ Neurobiological Predictors of Huntington's Disease (PREDICT-HD), NINDS NS40068, 11/01-10/06, _____

Coordination Center Director _____ Prospective Huntington At-Risk Observational Study (PHAROS). Huntington's Disease Society of America and Hereditary Disease Foundation. 5/99-12/01, _____

Multicenter Research Groups

Executive Committee and Coordination Center Director, Parkinson Study Group (PSG)
Executive Committee and Coordination Center Director, Huntington Study Group (HSG)
Coordination Center Director, Charles A. Dana Consortium for the Treatment of HIV Dementia
Neurology Subcommittee, AIDS Clinical Trial Group (ACTG)
Consultant & Subproposer, European Network for Striatal Transplantation in HD (NEST-HD)
Scientific Advisor, Alzheimer Disease Cooperative Study (ADCS) (_____)

Peer Review

Funding Review

NIMH contract review. NIMH, ADAMHA, Clinical Trial in HIV Dementia. June 1990

NIMH contract review. NIMH, ADAMHA, Clinical Trial in HIV Dementia. April 1992

GCRC site visit, NCRR, NIH. Johns Hopkins University GCRC. May 14-15, 1992

NIMH contract concept review NIMH, NIH, Clinical Trial in HIV Dementia, March 1993

NIH contract concept review, NINDS. NIH, Huntington's Disease Research Roster, October 1993.

RO-1 special review committee, NIMH, NIH, Clinical Trial in HIV Pain Syndrome, November 5, 1993

NIMH Ad Hoc Grant Reviewer, Neuroleptic Induced Movement Disorders in Schizophrenics, February 1998

NIH-NINDS RFP 98-07 Review, National Research Roster of Huntington's Disease Patients and Families, June 1998

NIMH Ad Hoc Grant Reviewer, Neuroleptic Induced Movement Disorders in Older Patients, June 1998

NINDS ZNS1 SRB-P (01) Review, Special Emphasis Panel, April 6, 1999

External Review Committee for Baltimore Huntington's Disease Center, September 14, 1999

NINDS ZNS1 SRB-P (01) Review, Special Emphasis Panel, November 19, 1999

Review Committee, University of Rochester Psychiatry Department Research Awards. 1997-2000

Member. NINDS Clinical Trials Study Section. 2000-present

Member. Huntington's Disease Society of America Research Grants Sub-Committee, 2000-present

Member. Scientific Review Board. University of California's Center for Medicinal Cannabis Research. 2000 – present

Member. Scientific Advisory Board, Hereditary Disease Foundation. 2002-present

Publication Review

Abstract Reviewer. Movement Disorders Section. American Academy of Neurology Annual Meeting. March 1996, April 1997

Ad Hoc Reviewer. New England Journal of Medicine. Archives of Neurology. Annals of Neurology. Movement Disorders. Journal of Acquired Immune Deficiency Syndromes. Journal of Pediatrics. Clinical Neuropharmacology. The Lancet

Editorial Board. Journal of Neuro-AIDS (R. Price. Editor)

Associate Editor. Neurology. 1997-2001

National Service

Member, Performance and Safety Monitoring Board for the Hypothermia During Intracranial Aneurysm Surgery Trial (IHAST 2), November 1999-

American Academy of Neurology, Computer and Information Systems Committee, November 1993-1999

American Academy of Neurology, Clinical Research Subcommittee, September 2001-

American Academy of Neurology, Subcommittee on Subspecialty Certification, 2000-2003

American Society for Experimental NeuroTherapeutics, Program Committee, 1999-

American Neurology Association, SPAC, 2003-

Movement Disorders Society, Scientific Issues Committee, 2003-

University Service

Neurology Department Quality Assurance Liaison 7/92-2/93

Neurology Out-Patient Department Task Force 10/92-10/93

Medical Student Faculty Advisor 9/92-12/97

Pharmacy and Therapeutics Committee 3/93-3/00

Member, Chair of Department of Biostatistics Search Committee 9/94-6/95

Member, Phase I Unit Committee 11/97-2/98

Member, Clinical Research Center Advisory Committee, 2/96-9/00

Member, Faculty Research Incentives Committee, 4/97-12/97

Member, Research Subjects Review Board, 9/97-

Member, Kornberg Research Awards Committee, 4/02-

Member, Review Committee for Institutional Pilot Project Funding, 5/0-

Professional Society Memberships

American Neurological Association, member 1996

American Academy of Neurology, fellow 1998

Movement Disorders Society

American Association for the Advancement of Science

World Federation of Neurology Research Committee on Parkinson's Disease & Related Disorders, 2001

American Society for Experimental NeuroTherapeutics 1998

Patient Care

Attending: Movement and Inherited Neurologic Disorders Unit.

1 day/week clinic and 1 month/year in-patient service

Consultation and In-patient Neurology Services 1 month/year

Articles (continued)

Kieburtz K, Ketonen L, Cox C, Grossman H, Holloway R, Booth H, Hickey C, Feigin A, Caine ED. Cognitive Performance and Regional Brain Volume in Human Immunodeficiency Virus Type 1 Infection. *Arch Neurol* 1996;53:155-158.

The Huntington Study Group (K Kieburtz, Corresponding Author), The Unified Huntington's Disease Rating Scale: Reliability and Consistency. *Movement Disorders* 1996;11:136-142.

Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Claude K, Sotack J, Greenamyre JT, Dunn C, Shoulson I. A Controlled Trial of Remacemide Hydrochloride in Huntington's Disease. *Movement Disorders* 1996;11:273-277.

Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I. Assessment of Coenzyme Q10 Tolerability in Huntington's Disease. *Movement Disorders* 1996;11:321-323.

CAPIT-HD Committee (Quinn N, Brown R, Craufurd D, Goldman S, Hodges J, Kieburtz K, Lindvall O, MacMillan, Roos R). Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). *Movement Disorders* 1996;11:143-150.

Ketonen L, Kieburtz K, Kazee AM, Tuite M. Putaminal iron deposition in HIV infections. *J NeuroAIDS* 1996;1:33-40.

Parkinson Study Group (Kieburtz K, primary author): Effect of lazabemide on the progression of disability in early Parkinson's disease. *Ann Neurol* 1996;40:99-107.

Dana Consortium on Therapy For HIV Dementia and Related Cognitive Disorders. Clinical Confirmation of the American Academy of Neurology Algorithm for HIV Associated Cognitive Motor Disorder. *Neurology* 1996;47:1247-1253.

Ketonen LM, Kieburtz K, Tuite MJ, Eskin T, Simon J. CNS Lymphoma in an AIDS Patient Involving the Posterior Fornix. *J. NeuroAIDS* 1996;3:43-49

Siesling S, Zwinderman AH, van Vugt JPP, Kieburtz K, Roos RAC. A shortened version of the motor section of the Unified Huntington's Disease Rating Scale. *Movement Disorders* 1997;12:229-234.

LeWitt P, Oakes D, Cui L and the Parkinson Study Group. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α -tocopherol. *Movement Disorders* 1997;12:183-189.

Kieburtz K, Price RW, Sidtis JJ, Hall C, Grundman M, McLaren C. Pilot Study of Didanosine in Patients With HIV Dementia. *J NeuroAIDS* 1997;1(4):1-5.

Sidtis JJ, Hall C, Price RW, Dafni U, Kieburtz K, Tucker T, Clifford DB. Neurological function in patients treated with 2'3'-dideoxyinosine. *J Neurovirology* 1997;3:233-240.

The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders (K Kieburtz, primary author) Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. *Neurology* 1997;49:142-146.

Articles (continued)

Stern Y, McDermott MP, Albert S, Palumbo D, Selnes OA, McArthur J, Sacktor N, Schifitto G, Kieburtz K, Epstein L, Marder KS and the Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Factors associated with incident human immunodeficiency virus-dementia. *Archives of Neurology*. 2001;58:473-479.

Huntington Study Group (K Kieburtz, primary author). A randomized, placebo-controlled trial of coenzyme Q₁₀ and remacemide in Huntington's disease. *Neurology* 2001;57:397-404.

Parkinson Study Group (J de Marcaida, primary author). Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. *Arch Neurol* 2001;58:1660-1668.

Tourette's Syndrome Study Group. Treatment of ADHD in children with tics. A randomized controlled trial. *Neurology* 2002;58:527-536.

Parkinson Study Group (K Marek, primary author). Dopamine transporter brain imaging to assess the effects of Pramipexole vs. levodopa on Parkinson disease progression. *JAMA* 2002;287:1653-1661.

Goetz CG, Leurgans S, Raman R and the Parkinson Study Group. Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. *Movement Disorders* 2002;17:283-288.

Shoulson I, Oakes, D, Fahn S, et al. Impact of sustained Deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial. *Ann Neurol* 2002;51:604-612.

Schifitto G, McDermott MP, McArthur JC, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. *Neurology* 2002;58:1764-1768.

Siderowf A, McDermott M, Kieburtz K, et al. Test-Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's Disease: Results from a Multicenter Clinical Trial. *Movement Disorders*. 2002;17:758-763.

Shults CW, Oakes D, Kieburtz, K, et al. Effects of Coenzyme Q₁₀ in Early Parkinson Disease. Evidence of Slowing of the Functional Decline. *Arch Neurol* 2002;59:1541-1550.

Clifford DB, McArthur JC, Schifitto G, Kieburtz K, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. *Neurology* 2002;59:1568-1573.

Parkinson Study Group. A controlled trial of Rasagiline in early Parkinson disease. The TEMPO study. *Arch Neurol* 2002;59:1937-1943

Sacktor, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. *J Neurovirol* 2002;8(2):136-42.

Kieburtz K. Designing neuroprotection trials in Parkinson's disease. *Ann Neurol* 2003;53(S3):S100-S109.

Letters, Book Reviews, Editorials

- Kieburtz K. Chronic cholinergic poisoning (letter to editor). *New Engl J Med*, 311:1439,1984.
- Kieburtz K, Moxley RT. Seizures after Carotid Endarterectomy (ltr to editor). *Arch Neurol* 48:131,1991.
- Kieburtz K, Caine ED. Secondary affective disorder in AIDS (ltr to editor). *Am J Psychiatry* 149:583-584, 1992.
- Schwid S, Ketonen L, Betts R, Richfield E, Kieburtz K. Cerebrovascular complications after primary varicella-zoster infection (ltr to editor). *Lancet* 340:669, 1992.
- Ketonen L, Kieburtz K, Tuite M. Use of gadolinium in MR brain imaging of HIV infected patients (letter to editor), *AJNR* 14:1325-6, 1993.
- Kieburtz K. HIV related myopathy (letter to editor), *Neurology*. 1994; 44:361.
- Penney JB, Shoulson I, Kieburtz K, Oakes D for the DATATOP Steering Committee & Investigators. Reply ltr to Study Design Problems of DATATOP Study Analysis. *Annals of Neuro* 1996;40:947-948.
- Kieburtz K (Book review) *Parkinson's Disease: From Basic Research to Treatment*, Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds), *J Am Ger Soc* 1994; 42(1):119.
- Kieburtz K. (Book review) *Parkinson's Disease and Movement Disorders*, Jankovic J, Tulos E (eds), *Arch Neurol* 1994;51:967-8.
- Kieburtz K (book review). *Movement Disorders: Neurologic Principles and Practice*. *Neurology*, 1998;50:1999.
- Kieburtz K. Entacapone. A Viewpoint. *CNS Drugs* 1997;8(1):89.
- McDermott M, Kieburtz K. Reply to Entacapone and motor fluctuations in Parkinson's disease. *Annals of Neurology*, 1998;44:292.
- Kieburtz K (editorial). Avoiding conflicts of interest. Responsibilities of authors, reviewers and editors. *Neurology* 1998;51:1527-1528.
- McArthur JC, Kieburtz K (edt) Of mice and men. A model of HIV encephalitis. *Neuro* 2000;54:284-285.
- Kieburtz K, Hubble J. Benefits of COMT inhibitors in levodopa-treated Parkinsonian patients: results of clinical trials. *Neuro* 2002;55:S42-5:discussion S46-50.
- Griggs RC, Kieburtz KD, Duffy CJ, McDermott MP. Message from the editors to our ad hoc reviewers. *Neuro* 2002;55:1766-9.
- Kieburtz K (Review). Antiglutamate therapies in Huntington's disease. *J Neural Transm Suppl* 1999;55:97-102.

Letters, Book Reviews, Editorials (continued)

Kieburtz K (book review). Clinical Trials in Neurology. Annals of Neurology, 2002;52:387.

Kieburtz K and McDermott M (editorial) Needed in MS. Evidence. not EVIDENCE. Neurology 2002;59:1482-1483.

Book Chapters, Invited Manuscripts

Kieburtz K, Schiffer RB. Neurologic manifestations of HIV infection. Neurol Clinics, 7(3):447-468, 1989.

Kieburtz K, Goldblatt D (editors) Neurology of HIV infection. Seminars in Neurology 12:1-82, 1992.

Jozefowicz RF, Berg M, Dimitropoulos T, Giang D, Gilmore J, Goodman A, Joynt R, Kieburtz K. Current Therapy in: Joynt RJ (ed) Clinical Neurology. J.B. Lippincott Co., Phil. PA, 1993.

Kieburtz K, Feigin A, Barbano, R. Neurologic Complications of Vitamin and Mineral Disorders in: Joynt RJ (ed) Clinical Neurology, J.B. Lippincott Co., Phil, PA, 1994 (revised 1999).

Jozefowicz RF, Benesch CG, Berg M, Dimitropoulos T, Gilmore J, Goodman A, Joynt R, Kieburtz K. Current Therapy in: Joynt RJ (ed) Clinical Neurology. J.B. Lippincott Co., Phil. PA, 1994.

Feigin A, Kieburtz K, Shoulson I. Treatment of Huntington's Disease and Other Choreic Disorders in: Kurlan R (ed) The Treatment of Movement Disorders, J.B. Lippincott Co., Phil, PA, 1995 337-364.

Kieburtz K, Shoulson I. Treatment of Parkinson's Disease with Deprenyl (Selegiline) and Other Monoamine Oxidase Inhibitors in: Olanow W, Jenner P, Youdim M (eds) Neuroprotective Approaches to the Treatment of Parkinson's Disease and Other Neurodegenerative Disorders, Academic Press Ltd., London, England, 1996 47-54.

Marshall FJ, Kieburtz K, McDermott M, Kurlan R, Shoulson I. Clinical Research in Neurology: From Observation to Experimentation (Chapter) for Neurologic Clinics. J. Riggs (ed), WB Saunders Co., Philadelphia, PA, 1996, 451-466.

Holloway R, Kieburtz K, Schifitto G. HIV-1 Infection and the Nervous System (Chapter) in: Joynt RJ (ed) Clinical Neurology. J.B. Lippincott Co., Philadelphia, PA, 1996.

Kieburtz K. Subacute Combined Degeneration For Current Therapy in Neurologic Diseases (Chapter). RT Johnson and JW Griffin (eds), Mosby-Year Book Inc., St. Louis, MO, 1997, 356-358.

Marshall FJ, Kieburtz K. Design and Interpretation of Clinical Trials in Neuroprotection (Chapter). Neuroprotection: Fundamental and Clinical Aspects, PR Bär & MF Beal (eds), Marcel Dekker, Inc., New York, 1997, 331-347, 457-464.

Shoulson I, Kieburtz K. Neuroprotective Therapy For Huntington's Disease (Chapter). Neuroprotection: Fundamental and Clinical Aspects, PR Bär & MF Beal (eds), Marcel Dekker, Inc., New York, 1997, 457-465.

Book Chapters, Invited Manuscripts (continued)

Lipton S, Kieburtz K, Bloom F. Adjunctive Therapies For HIV-1 Associated Cognitive Motor Complex (Chapter), The Neurology of AIDS, Gendelman, Lipton, Epstein and Swindells (eds), Chapman & Hall, New York, 1998.

Kieburtz K, Holloway R. Neurologic Complications of HIV Infection (Chapter), Principles and Practice of Infectious Diseases, 5th Edition, Mandell, Bennett, and Dolin (eds), W.B. Saunders Company, New York, 1998.

Kieburtz K. Antiglutamate therapies in Huntington's disease (Chapter). Advances in Research on Neurodegeneration, Volume 6, W. Poewe & G. Ransmayr (eds), Springer-Verlag/Wien, New York, 1999.

Blindauer KA, Benesch CG, Counihan T, Schwid SR, Toczek M, Wollman E, Holloway RG, Kieburtz K. Current Therapy in: Joynt RJ (ed) Clinical Neurology, J.B. Lippincott Co., Phil, PA, 2000.

Kieburtz K, Shoulson I. Therapeutic Trials in Huntington's Disease (Chapter) in Huntington's Disease, 3rd Edition, G Bates, P Harper, L Joens (eds), Oxford University Press, in press.

Gasser T and Kieburtz K. Huntington's disease and Sydenham's chorea (Chapter) in Course and Treatment of Neurological Diseases, 2nd Edition, T Brandt, LR Caplan, J Dichgans, HC Diener, C Kennard (eds), Academic Press, in press.

Abstracts

Kieburtz K, Madan M, Vakil N, Schiffer RB. Vitamin B-12 deficiency in AIDS. Ann Neurol, 26(1):153, 1989.

Kieburtz K, Ricotta JJ, Moxley RT. Seizures after carotid endarterectomy. Ann Neurol, 26(1):132, 1989.

Ketonen L, Kieburtz K, Zettelmaier A, Simon J, Kido D. MRI changes in HIV related cognitive impairment Radiology, 173(P):329, 1989.

Tuite M, Ketonen K, Kieburtz K, Zettelmaier A, Kido D. MRI changes in HIV related affective disorders. Neurological and Neuropsychological Complications of HIV infection Monterey CA. June 1990. Ann Neurol 28:297, 1990.

Kieburtz K, Como P, McDermott M and the Parkinson Study Group. Neuropsychological evaluation in early untreated Parkinson's Disease. Ann Neurol 28:236, 1990.

Ketonen L, Kieburtz K, Tuite M, Kido D. The Value of Gadolinium in MR Imaging of HIV Infected Patients. Neurol 41(suppl 1):253, 1991.

Pelusio R, Miller C, Orme C, Andrews M, Casaceli C, Lieou J, Kieburtz K, Wixsom J, Shoulson I, and the Parkinson Study Group. Use of computer applications to facilitate retroactive updates to a database. Controlled Clinical Trials 12:707, 1991.

Abstracts (continued)

Kieburtz K, Eskin TE, Ketonen L, Tuite M. Stroke and cerebral vasculopathy in AIDS. *Neurology* 42 (suppl 3):250, 1992.

Parkinson Study Group. Assessment of short-term tolerability of lazabemide (Ro 19-6327) in untreated Parkinson's disease. *Movement Disorders* 7:293-294, 1992.

Ketonen L, Kieburtz K, Kazee A, Tuite M. Putaminal iron deposition in HIV infection. *Neurol* 1993, 43; 4:A255.

Rudolph A, Pelusio RM, McManus J, Bordwell KL, Kieburtz K, Dorflinger E, Shoulson I and the Parkinson Study Group. Promoting enrollment in a multi-center clinical trial. *Controlled Clin Trials* 1993, 14:438.

Parkinson Study Group (K Kieburtz, Medical Director, Steering Committee). The impact of extended deprenyl treatment in Parkinson's disease patients not requiring levodopa therapy. *Ann Neurol* 1993, 34:263.

Parkinson Study Group (K Kieburtz, Medical Director, Steering Committee). Effects of sustained deprenyl and tocopherol therapy in levodopa treated parkinsonian patients. *Ann Neurol* 1993, 34:247.

Parkinson Study Group (K Kieburtz, Medical Director, Steering Committee). Cerebrospinal fluid homovanillic acid changes in patients with mild early parkinsonism. *Movement Disorders* 1993, 8:410.

Parkinson Study Group (K Kieburtz, Medical Director, Steering Committee). Controlled trial of lazabemide in levodopa treated Parkinson's disease. *Movement Disorders* 1993, 8:411.

Feigin A, Kieburtz K, Como P, Hickey C, Steinberg K, Bordwell K, Sotack J, Shoulson I. Predictors of disease progression in Huntington's disease. *Proceedings of the 15th International World Federation of Neurology Workshop on Huntington's Disease*, abstract #54, September 2, 1993.

Kieburtz K, McDermott M, Growdon J, and the Parkinson Study Group. Cognition in PD: the DATATOP Study. *New Trends Clin Neuropharm* 1994; 8:201.

Feigin A, Kieburtz K, Como P, Abwender D, Zimmerman C, Hickey C, Steinberg K, Bordwell K, Sotack J, Orme C, Shoulson I. An open-label trial of coenzyme Q10 (CoQ) in Huntington's disease (HD). *Neurology* 1994; 44:A397-8.

Kieburtz K, Ketonen L, Grossman H, Cos C, Holloway R, Booth H, Hickey C, Haaser R, Feigin A, Caine E. Neuropsychological performance and caudate volume in HIV-1 infection. *Ann Neurol* 1994; 36:300.

Kieburtz K, McDermott M, Feigin A, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Bordwell K, Sotack C, Dunn C, Greenamyre JT, Shoulson I. A controlled trial of the glutamate antagonist remacemide hydrochloride in Huntington's disease. *Soc for Neuroscience. Abstracts* 1994;20:1256.

Casaceli C, Sotack J, Orme C, Rudolph A, Kieburtz K, and the Parkinson Study Group. Electronic events coding. *Controlled Clinical Trials* 1994;15:92.

Abstracts (continued)

Huntington Study Group (K Kiebertz, Executive Committee). Internal Validity and Consistency of the Unified Huntington's Disease Rating Scale (UHDRS). *Neurology*, 1995;45 (Suppl 4):A254.

Parkinson Study Group (K Kiebertz, Presenter). Effect of Lazabemide on the Progression of Disability in Early Parkinson's Disease. *Neurology*, 1995;45 (Suppl 4):A291.

Kiebertz K, McDermott M, Marshall FJ, Feigin A, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Bordwell K, Sotack J, Greenamyre, Dunn C, Shoulson I. Evaluation of the Glutamate Antagonist Remacemide Hydrochloride in Huntington's Disease. *Neurology*, 1995;45 (Suppl 4):A254.

The Parkinson Study Group (K Kiebertz, Presenter). Dose Ranging Study of The Safety and Efficacy of the Dopamine Agonist Pramipexole in Early Parkinson's Disease. *Movement Disorders*, 1995;10:691.

Marshall FJ, Kiebertz K, MacDonald M, Shih C, Feigin A, Steinberg K, Orme C, Claude K, Zimmerman C, Sotack J, Srinidhi J, Gusella J, Shoulson I. The Relationship Between CAG Repeat Length and Rate of Motor and Cognitive Change in Huntington disease (HD). *Movement Disorders*, 1995;10:696.

Schifitto G, Kiebertz K, Palumbo D, Zimmerman C. Dehydroepiandrosterone Sulphate: A Potential Metabolic Marker of HIV-1-Associated Cognitive/Motor Complex. *Neurology*, 1996;46:A465.

Dana Consortium on Therapy for HIV Dementia (K Kiebertz, Presenter). Neurologic and Mood Dysfunction Are Associated With Impairment of Cognition and Independent Function in HIV Infection. *Neurology*, 1996;46:A463.

Richard I, Kurlan R, Tanner C for the Parkinson Study Group. Serotonin Syndrome and the Combined Use of Deprenyl and an Antidepressant in Parkinson's Disease. *Neurology* 1996; 46:A374.

Huntington Study Group (F Marshall, Presenter). Interlaboratory Variability of (CAG)_n Determinations in Huntington's Disease. *Neurology*, 1996;46:A258.

Albert SM, Marder K, Dooneief G, McDermott M, Stern Y, Selnes O, MacArthur J, Epstein L, Kiebertz K, Mayeux R. Defining and Staging HIV-1-Associated Dementia: Baseline Results From The Dana Consortium on Therapy For HIV Dementia. *J of NeuroVirology*, 1996;2:30.

Dana Consortium For Treatment of HIV Dementia. Antioxidant Treatment in HIV Dementia. *J of NeuroVirology*. 1996;2:41.

Schifitto G, Kiebertz K, Palumbo D, Zimmerman C. Autonomic Dysfunction in HIV-1 Associated Cognitive Impairment. *J of NeuroVirology*. 1996;2:49.

Parkinson Study Group (Kiebertz K presenter). The COMT Inhibitor Entacapone Improves Parkinsonian Features in Fluctuating Patients. *Movement Disorders*. 1996;11(1):268.

Huntington Study Group (Marshall FJ, presenter). Safety and Tolerability of the Free- Radical Scavenger OPC-14117 in Huntington's Disease. *Movement Disorders*. 1996;11(1):59.

Abstracts (continued)

Parkinson Study Group (PSG) [Kieburtz K primary author] and Nordic Study Group (NOMECOMT) [Rinne UK primary author]. The COMT Inhibitor Entacapone Increases "On" Time in Levodopa-Treated PD Patients with Motor Fluctuations: Report of Two Randomized, Placebo-Controlled Trials. *Movement Disorders*, 1996, 11(5):595.

Schifitto G, Palumbo D, Hickey C, Zimmerman C, Buck B, Gruning J, Hauptfleish S, McDermott M, Kieburtz K. Psychiatric disorders and cognitive dysfunction in HIV infected individuals, *Ann Neurol*, 1996, 40(3):506.

Schifitto G, Kieburtz K, Fitzgerald T, Soucier H, Evans T. Dysfunction of the Autonomic Nervous System Alters the Pattern of Cytokine Production in HIV Infected Individuals. XI International Conference on AIDS Abstracts July 7-12, 1996, p. 73.

Schifitto G, Zimmerman C, Hickey C, Kieburtz K. Autonomic Dysfunction and Distal Sensory Neuropathy in HIV Infection: Role of Macrophage Activation. *Clinical Autonomic Research* 1996;6:283.

Marshall FJ, Taylor S, Huntington Study Group (HSG). Aggression and irritability in Huntington Disease: A survey of treatment patterns. *Neurology* 1997;48:A49.

Growdon JH, Kieburtz K, McDermott M, Panisset M, Friedman JH, and the Parkinson Study Group. Levodopa improves motor function without impairing cognition in mild non-demented PD patients. *Movement Disorders* 1997;12:57.

Kieburtz K, Yiannoutsos CP, Simpson D, and the AIDS Clinical Trial Group Protocol 242 Study Team. A double-blind, randomized clinical trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. *Ann Neurol* 1997;42:429.

Parkinson Study Group (Marek K). DOPASCAN and SPECT is a sensitive and specific diagnostic tool for parkinsonism. *Movement Disorders* 1997;12:835.

Panisset M, Siderowf A, McDermott M, Kieburtz K, Friedman J, Growdon J, and the Parkinson Study Group. Baseline predictors of subsequent dementia in the DATATOP cohort. *Movement Disorders* 1997;12:836.

Parkinson Study Group (Shoulson I). Clinical outcome following placebo-controlled withdrawal of deprenyl (selegiline) among levodopa-treated DATATOP subjects. *Movement Disorders* 1997;12:838.

Carter JH, Stewart BJ, Archbold PG, Inoue I, the Parkinson Study Group. Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. *Neurology* 1997;48:A180.

Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in HIV-associated cognitive impairment. *Annals of Neurology* 1997;42:425.

Albert SM, Marder K, Todak G, Clouse R, Stern Y, Mayeux R, McArthur J, McDermott M, Kieburtz, Epstein L. Functional status of patients with HIV-1-associated cognitive motor disorder. *Annals of Neurology* 1997;42:393.

Abstracts (continued)

Rajput AH, Jankovic J, McDermott M and the Parkinson Study Group. Diagnostic accuracy in early Parkinson's disease. *Neurology* 1997;A369.

Parkinson Study Group (Shoulson I, primary author). Clinical outcome following placebo-controlled withdrawal of deprenyl (selegiline) among levodopa-treated DATATOP subjects. *Movement Disorders* 1997; 12:838.

Friedman JH, Lannon MC, Factor S, Comella C, Parsa M, Pfeiffer R, Richards I, Kurlan R, and the Parkinson Study Group. Low dose clozapine for the treatment of drug-induced psychosis (DIP) in idiopathic Parkinson's disease (PD): Results of the double-blind, placebo-controlled PSYCLOPS trial. *Neurology* 1998;50:A70.

Schifitto G, McDermott M, Evans T, Kieburtz K. Relationship between TH1 and TH2 cytokines, autonomic function and dehydroepiandrosterone sulfate (DHEAS) in HIV-1 infected individuals. *Neuroimmunomodulation* 1998;5:43-44.

The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders (Schifitto G). Cognitive and functional outcomes in HIV dementia clinical trials. *J Neurovirology* 1998; 4:346.

Marder K, Albert SM, McDermott M and the Dana Consortium on Therapy for HIV Dementia and Related Disorders. Prospective study of neurocognitive impairment in HIV(Dana cohort): dementia and mortality. *J Neurovirology* 1998; 4:358.

Stern Y, Marder K, Albert SM, McDermott M and the Dana Consortium for Therapy of HIV Dementia and Related Disorders. The Dana cohort: predictors of HIV dementia. *J Neurovirology* 1998; 4:367.

Factor SA and the Parkinson Study Group. Clozapine for the treatment of drug induced psychosis in Parkinson's disease: results of the 12 week open label follow up in the PSYCLOPS trial. *Movement Disorders* 1998;13(Suppl 2):241.

Marder SK, Zhao H, Myers RH, Cudkowicz M, Penney JB, Kieburtz K, et al. Rate of functional decline in Huntington's disease. *Neurology* 1999;52 (Suppl 2):A376.

Parkinson Study Group. The glutamate antagonist remacemide improves motor performance in levodopa-treated Parkinson's disease. *Neurology* 1999;52 (Suppl2):A262.

Parkinson Study Group. Pramipexole in ethnic minorities with Parkinson's Disease (PD): Safety, Tolerability and Efficacy (PRIME). *Movement Disorders* 1999;14:901.

Hogarth P, Rosas D, Zhao H, Kayson E, Oakes D, Kieburtz K, et al. A study of inter-rater reliability of motor diagnosis of Huntington's disease. *Movement Disorders* 1999;14:901.

Holloway R, McDermott M, Kieburtz K, et al. Estimating the incidence of motor complications in patients starting levodopa: Implications for clinical trials. *Movement Disorders* 1999;14:905.

Volk M, Marshall F, McDermott M, Kieburtz K and the Huntington Study Group. Electrocardiographic manifestations of Huntington's disease. *Movement Disorders* 1999;14:902.

Abstracts (continued)

Kiebertz K. Issues in transplantation for Huntington's disease. *Cell Transplantation* July/Aug 1999;8:456-457.

Hogarth P, Brocht A, Kayson E, Orme C, Zhao H, Shoulson I and the Huntington Study Group. Gender disparity in study participation among individuals at risk for Huntington's disease. *Movement Disorders* 2000;5:1042.

Goetz GC, Leurgans S, Raman R and the Parkinson Study Group. Placebo-related improvements in motor function in early Parkinson's disease. *Annals of Neurology* 2000;48:433.

Wheelock V, Tempkin T, Marder K, Nance M, Myers R, Zhao H and the Huntington Study Group. Do motor, behavioral, or psychiatric correlates predict the need for institutional care in patients with Huntington's disease? *Annals of Neurology* 2000;48:467.

Schifitto G, Simpson D, Yiannoutsos C, McArthur J, et al. Long-term treatment with open label nerve growth factor for HIV-associated sensory neuropathy. *Neurology* 2000;54 (Supl 3): A321.

Schifitto G, Marder K, Sacktor N, McDermott MP, McArthur JC, Kiebertz K, Epstein LG, for the Dana Consortium. Incidence and risk factors of human immunodeficiency virus-associated distal sensory polyneuropathy in the Dana Cohort. *Annals of Neurology* 2000;48:484.

Huntington Study Group (K Kiebertz, presenter). Placebo-controlled trial of creatine in Huntington's disease. *Neurology* 2001;56:A386.

Parkinson Study Group (K Marek, presenter). Comparison of imaging and clinical endpoints in subjects participating in the CALM-PD study. *Neurology* 2001;56:A73.

Zhang L, Nie ZY, Liu Y, et al. Prevalence of Parkinson's disease in Linxian County, China. *Neurology* 2001;56:A222.

Parkinson Study Group (K Blindaer, presenter). Tyramine challenge to assess the safety of Rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO study). *Neurology* 2001;56:A345.

Parkinson Study Group (A Siderowf, presenter). Earlier treatment with Rasagiline may attenuate (UPDRS) progression of PD. *Movement Disorders* 2001;16:981.

Parkinson Study Group (KA Blindauer, presenter). Defining responder status in a clinical trial of the rotigotine transdermal system (SPM-962) in early Parkinson's disease. *Movement Disorders* 2001;16:981-982.

Huntington Study Group (MA Shinaman, presenter). Willingness to consent for future genetic testing by individuals at risk for or with Huntington's disease: A preliminary report. *Movement Disorders* 2001;16:987.

Blindauer KA and the Parkinson Study Group. A multi-center, randomized, double-blind pilot study comparing TV-1203 and levodopa tablets in advanced Parkinson's disease patients with response fluctuations. *Movement Disorders* 2001;16:987.

Abstracts (continued)

Noyes K, Zwanziger J, Dick AW, Holloway R and the Parkinson Study Group. Do dopaminergic complications predict quality of life in Parkinson's disease? *Movement Disorders* 2001;16:988.

DeMarcaida JA, Schwid S, Blindauer K, Fahn S, Kieburtz K, Marek K, Oakes D, Stern M, Shoulson I and the Parkinson Study Group. Current opinions on appropriate endpoints in Parkinson's disease-modifying trials. *Movement Disorders* 2001;16:989-990.

Marshall FJ, Marder K, Taylor S, Zhao H and The Huntington Study Group (HSG). The frequency and severity of disruptive behavior and irritability in Huntington's disease. *Movement Disorders* 2001;16(1):S45.

Kieburtz K. Conduct of Clinical Trials: The Principal Investigator's Perspective. *Archives of Neurology* 2002;59:325.

Hamilton JM, Corey-Bloom J, Thomas RG, Peavy G, Jacobson MW and the Huntington Study Group. Correlates of Weight Change in Huntington's Disease. *Neurology* 2002; 58:A309.

Parkinson Study Group (RG Holloway, presenter). Pramipexole versus levodopa as initial treatment for Parkinson disease: A four-year randomized controlled trial. *Neurology* 2002;58:A81.

Parkinson Study Group (K Marek, presenter). Pramipexole versus levodopa: Effects on Parkinson disease progression assessed by dopamine transporter imaging. *Neurology* 2002;58:A82.

Mahant N, McCusker EA., Graham S and the Huntington Study Group. Huntington disease: Does mode of onset determine disease course? *Neurology* 2002;58:A333.

Marder, K, Louis ED, Parides M, Kieburtz K, Orme C, Shoulson I and the Huntington Study Group. Longitudinal evaluation of motor signs in Huntington's disease. *Neurology* 2002;58:A333.

Kayson EP and the Huntington Study Group/PHAROS Investigators. Safety and feasibility of the prospective Huntington at risk observational study (PHAROS): A preliminary report. *Neurology* 2002;58:A334.

**APPEARS THIS WAY
ON ORIGINAL**